New Sales Initiatives and Executive to Aid
in Driving Electromedical Technologies Revenue
-
Company adds New Sales Director with 12 years of Experience Selling
and Training the Wellness Pro+
- Kathy
Strand, R.N. has Sold Over 3,000 Wellness Pro+ Devices and Treated
28,000+ Patients
- EMED
Plans to On-Board 200 Active Sales Distributors by
Year-End
SCOTTSDALE, AZ -- May 6, 2021 -- InvestorsHub NewsWire
-- Electromedical Technologies,
Inc. (OTCQB:
EMED)
(the "Company"), a pioneer in the development and manufacturing
of bioelectronic
devices,
including the FDA cleared WellnessPro+®
is pleased to
announce that the Company
has
retained Kathy
Strand,
R.N. as
its Director of Sales and Training. Ms. Strand is a Registered
Nurse with twelve years of experience
in
selling
more than
3,000 units of
the Company's
flagship device – the
WellnessPro+, and treating over 28,000
patients.
Ms. Strand first
learned about the Company and the
WellnessPro+ when her mother was diagnosed
with incurable and intractable pain, more than twelve years
ago. Echoing the stories of
many other users
of the WellnessPro+, doctors informed Ms. Strand
and her family that there was nothing that could be done to relieve
her mother's pain, except through the use
of prescription opioids.
After Ms. Strand
learned about the
WellnessPro+, her mother began treatments
which resulted in immediate and life changing pain relief. Ms.
Strand joined the Wellness Pro+ community and became a sales
representative and evangelist
for the
Company. Ms. Strand has
advised
patients, doctors, therapists,
professional
sports teams, schools and university
athletic departments, hospitals, and animal therapy
departments on its use, with
outstanding sales success, led by favorable patient
outcomes.
As the
Director of Sales
and Training for EMED, Ms. Strand will be
responsible for sales of the
Wellness Pro+, collaborating with leadership
on the
Company's social media efforts and
outreach.
Ms. Strand's sales focus will include educating the public on the
benefits of use of the Wellness Pro+ and
engaging NEW WellnessPro distributors in
every state.
Ms. Strand will also actively host weekly
educational training sessions and ongoing support meetings to help
new customers use
their new
WellnessPro+ units. The Company expects
that these initiatives will help
drive product awareness and
new sales
of the
WellnessPro+. As awareness of the
product's effectiveness
in relieving
intractable pain increases, the Company
plans to
add
new
sales
representatives and distributors
to
meet potential
increases in demand.
Matthew Wolfson,
Founder and CEO of EMED, noted, "We are excited to have Kathy
part of our team and as our first sales director.
She is the
natural choice
to lead
our efforts given her medical background
and
medical
device market experience. Plus, her success in selling the
WellnessPro+ speaks for
itself. She has sold around 3,000 WellnessPro
devices since she
joined our company in a sales
representative/distributor role over 10 years ago.
Her
ability
to drive
sales
though
training and social media
are critical cogs
in our 2021 distributor and sales expansion plans.
By year-end, we plan to have at least 200
active distributors. We have already on boarded
37
NEW
distributors
this year and we haven't even
fully
commenced our distribution
program. Thus,
we expect meaningful
product sales from these channels and
additional distributors
may occur in the second
half of 2021.
Kathy Strand
commented, "I have participated in dozens of trade shows and have
seen many of the devices out there in the market today - this
device helped thousands of people get their lives back and feeling
good again. I have never seen a more effective
device to battle chronic pain. I believe
that the WellnessPro
+ is the best there is on
the market today!"
About
Electromedical Technologies
Headquartered in
Scottsdale, Arizona, Electromedical
Technologies, Inc. is a commercial stage, FDA cleared,
bioelectronic medical device manufacturing company initially
focused on the treatment of various chronic, acute, intractable,
and post-operative pain conditions. Through University collaboration
agreements, the Company is working to develop
a comprehensive research program in defining the effects of
electro-modulation on the human body. By studying the impacts of
electrical fields in cell signaling and effects on virus assembly
and immune responses, the Company's goal is
to reduce
pain and improve overall human wellbeing. The
Company's current
FDA
cleared product
indications are for chronic, acute, post traumatic and
post-operative, intractable pain relief. For more information,
please
visit
www.electromedtech.com.
Safe Harbor
Statement
This release
contains forward-looking statements that are based upon current
expectations or beliefs, as well as a number of assumptions about
future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which
they are based are reasonable, we can give no assurance or
guarantee that such expectations and assumptions will prove to have
been correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend," or
"project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous factors and uncertainties,
including but not limited to: adverse economic conditions,
competition, adverse federal, state and local government
regulation, international governmental regulation, inadequate
capital, inability to carry out research, development and
commercialization plans, loss or retirement of key executives and
other specific risks. To the extent that statements in this press
release are not strictly historical, including statements as to
revenue projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions,
events conditioned on stockholder or other approval, or otherwise
as to future events, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks
and uncertainties that could cause actual results to differ
materially from the statements made.
Corporate
Contact:
Electromedical Technologies,
Inc.
Hanover
International
Tel:
1.888.880.7888
email:
ir@electromedtech.com
https://electromedtech.com